Pharma BD Deal Intelligence
F. Hoffmann-La Roche AG / Hansoh Pharmaceutical Group Co. Ltd.
2025 · Licensing/Option · $1.5B · Complete
Hansoh Pharmaceutical granted Roche an exclusive license to HS-20110, a CDH17-targeting antibody-drug conjugate using a clinically validated topoisomerase inhibitor payload, for all territories outside the Chinese Mainland, Hong Kong, Macau and Taiwan. Roche pays $80 million upfront with up to $1.45 billion in milestone payments - roughly $1.53 billion in total - plus royalties on future sales. HS-20110 is in a global Phase 1 trial in China and the United States for colorectal cancer and other solid tumors.
This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal, once/if it closes.
Key facts
- Announced Oct 17, 2025
- Deal value $1.5B
- Deal type Licensing/Option
- Therapeutic area Oncology
- Indications Colorectal cancer and other solid tumors
- Key assets HS-20110
- Mechanism CDH17-targeting antibody-drug conjugate with topoisomerase I inhibitor payload
Related deals
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals
More: 2025 deals · F. Hoffmann-La Roche AG deals · Oncology deals